FDA approves Pfizer's biosimilar Ruxience

24 July 2019
pfizer_pills_drugs_big

In what has been a very active week for the US regulator in terms of approving new biosimilar medicines, the US Food and Drug Administration has approved a copy version of the leukemia drug sold by Roche (ROG: SIX) subsidiary Genentech as Rituxan (rituximab).

Pfizer (NYSE: PFE) late Tuesday announced the FDA has approved Ruxience (rituximab-pvvr) for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

Roche’s MabThera/Rituximab (rituximab) generated first-quarter 2019 global sales 1.67 billion Swiss francs ($1.7 billion), down 1.3% year-on-year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars